Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Sep 2015 15:12

RNS Number : 8961X
Oxford Biomedica PLC
02 September 2015
 

 

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Oxford Biomedica PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Third National Swedish Pension Fund

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

2015-09-01

6. Date on which issuer notified:

2015-09-02

7. Threshold(s) that is/are crossed orreached: vi, vii

3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0006648157

78,317,715

78,317,715

77,176,027

77,176,027

2.99%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

77,176,027

2.99%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

15. Contact telephone number:

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Third National Swedish Pension Fund

Contact address

(registered office for legal entities)

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 100

Other useful information

(at least legal representative for legal persons)

 

Mikael Sedolin

B: Identity of the notifier, if applicable

Full name

 

Sebastian Mossfeldt

Contact address

 

Vasagatan 7, 111 91 Stockholm, Sweden

Phone number & email

 

+468-555 17 162, Sebastian.mossfeldt@ap3.se

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUASRVRAKRAR
Date   Source Headline
7th Apr 20147:00 amRNSOXB completes patient recruitment into RetinoStat
21st Mar 20147:00 amRNSOXB Present at Regen Med Investor Day
17th Feb 20147:00 amRNSOxford BioMedica and Sanofi Amend Terms for Ocular
17th Jan 20144:40 pmRNSSecond Price Monitoring Extn
17th Jan 20144:35 pmRNSPrice Monitoring Extension
10th Jan 20147:00 amRNSPublication of ProSavin Phase I/II Study
9th Jan 201412:19 pmRNSOxford BioMedica to Present at Biotech Showcase
6th Jan 201410:28 amRNSOxford Biomedica PLC - General Meeting
18th Dec 20137:00 amRNSOXB option agreement with GSK
11th Dec 20137:00 amRNSCIRCULAR & GENERAL MEETING NOTIFICATION
22nd Nov 201312:38 pmRNSDirector/PDMR Shareholding
19th Nov 20137:00 amRNS£5 million Loan Facility from Lead Shareholder
19th Nov 20137:00 amRNSInterim Management Statement
17th Oct 20137:00 amRNSAgreement to Resume Clinical Trials
19th Sep 20137:00 amRNSDirector/PDMR Shareholding
17th Sep 20131:06 pmRNSBlock Listing Return
12th Sep 201311:18 amRNSOxford BioMedica plc Director's Share Purchase
11th Sep 20131:01 pmRNSOxford BioMedica Wins Significant Funding
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20134:08 pmRNSTR1 Form
29th Aug 20137:00 amRNSInterim Results 2013
28th Aug 20137:00 amRNSUS$1 million Milestone Payment from Pfizer
14th Aug 20131:00 pmRNSAnnounced as Funding Competition Winner
29th Jul 20137:00 amRNSPublication of TroVax Phase II Analyses
23rd Jul 20137:00 amRNSNotice of Interim Results
16th Jul 201311:20 amRNSDirector/PDMR Shareholding
1st Jul 20137:00 amRNSUpdate on Glaucoma-GT
28th Jun 20137:00 amRNSTotal Voting Rights
20th Jun 201311:15 amRNSDirector/PDMR Shareholding
19th Jun 201311:00 amRNSTR-1: Notification of Major Interest in Shares
12th Jun 20137:00 amRNSDirectors' Interests in Share Options
10th Jun 201312:59 pmRNSDirector/PDMR Shareholding
10th Jun 201312:59 pmRNSTR-1: Notification of Major Interest in Shares
10th Jun 20137:00 amRNSDirector's Share Purchase
6th Jun 201311:45 amRNSResult of AGM
6th Jun 20137:00 amRNSChange of Adviser and Broker
6th Jun 20137:00 amRNSManagement and Board change
5th Jun 201310:43 amRNSTR-1: Notification of Major Interest in Shares
3rd Jun 20137:00 amRNSClinical Trial Update
24th May 201310:00 amRNSBLOCK LISTING RETURN
16th May 20137:00 amRNSInterim Management Statement
9th May 20139:00 amRNSUpdate from ARVO 2013
3rd May 20132:00 pmRNSHolding(s) in Company
3rd May 20132:00 pmRNSDirector/PDMR Shareholding
1st May 20137:03 amRNSCollaboration with Novartis
17th Apr 20131:00 pmRNS2012 ANNUAL REPORT & ACCOUNTS & AGM NOTIFICATION
7th Mar 20137:00 amRNSInitiation of PII Collaborative Study for TroVax
27th Feb 20137:00 amRNSPreliminary Results
25th Jan 20134:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.